RxDoctor Payments Data

Thomas Martin, DO

Gastroenterology · Clive, IANPI 1417908922

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 30.3% of the total. 2025 is the largest year on record at $671, 2.6 times the $258 reported in 2019.

$2,215in general payments, 2019–2025

Across 135 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$671
  • Johnson & Johnson$650
  • Takeda Pharmaceuticals U.S.A., Inc.$118
  • Bristol Myers Squibb$102
  • Lumendi LLC$93
  • Lilly USA, LLC$92
  • plus $489 from 16 others

What the payments were for

  • Food & beverage$2,215100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,215 in reported general payments places this provider in the 75th percentile of 113 gastroenterology providers in Iowa.

See all gastroenterology providers in Iowa

Medicare billing

Part B allowed, 2024
$145,833
Medicare patients
394
Services billed
3,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide44$33,245
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates215$13,537
Dexlansoprazole DrDexlansoprazole26$5,155
Pantoprazole Sodium469$3,471
Mesalamine22$3,200
Budesonide EcBudesonide22$3,181
Lubiprostone16$2,977
Budesonide DrBudesonide27$2,639
Famotidine121$1,081
Omeprazole128$1,013
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine66$961
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg31$598
Metoclopramide Hcl65$233
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl13$210
Ondansetron Hcl134$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$671$33,24544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 113 gastroenterology providers in Iowa.

Other gastroenterology in Clive

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →